Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9574293 | 0.86 | PTGDR2 (0.44) | PTGDR2POLBMAPK1CYP19A1PRKCZ | |
| SCHEMBL29141195 | 0.81 | POLB (0.49) | POLBMAPK1RAB9AARCES2 | |
| SCHEMBL7618735 | 0.81 | KMT2A (0.55) | — | |
| SCHEMBL17891560 | 0.79 | PTGER4 (0.56) | PTGDR2POLBMAPK1CES2CES1 | |
| SCHEMBL29074270 | 0.79 | CYP19A1 (0.45) | PTGDR2POLBMAPK1CYP19A1AR | |
| SCHEMBL5827345 | 0.79 | CYP19A1 (0.45) | PTGDR2POLBMAPK1CYP19A1AR | |
| SCHEMBL23675461 | 0.78 | POLB (0.44) | PTGDR2POLBMAPK1PRKCZCES2 | |
| SCHEMBL5827236 | 0.78 | ALDH1A1 (0.47) | POLBMAPK1CYP19A1ARCES1 | |
| SCHEMBL9194437 | 0.76 | DPP4 (0.58) | POLBMAPK1ARCES1HTR7 | |
| SCHEMBL6645015 | 0.75 | RAB9A (0.61) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289554-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3458463-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | The University Court Of The University of Edinburgh (GB) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017199028-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289554-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | MCL1, DNPEP, PPOX | PTGDR2 505/4885POLB 1723/4885MAPK1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.